Bausch Health Companies Inc to Post Q3 2019 Earnings of $1.06 Per Share, Piper Jaffray Companies Forecasts (NYSE:BHC)

Bausch Health Companies Inc (NYSE:BHC) – Equities research analysts at Piper Jaffray Companies boosted their Q3 2019 EPS estimates for Bausch Health Companies in a report issued on Tuesday, August 6th, according to Zacks Investment Research. Piper Jaffray Companies analyst D. Amsellem now forecasts that the company will post earnings of $1.06 per share for the quarter, up from their previous forecast of $1.02. Piper Jaffray Companies has a “Buy” rating and a $29.00 price objective on the stock. Piper Jaffray Companies also issued estimates for Bausch Health Companies’ Q4 2019 earnings at $1.06 EPS, FY2019 earnings at $4.18 EPS, Q1 2020 earnings at $0.85 EPS, Q3 2020 earnings at $1.20 EPS, Q4 2020 earnings at $1.28 EPS, FY2020 earnings at $4.48 EPS, FY2021 earnings at $4.99 EPS, FY2022 earnings at $5.46 EPS and FY2023 earnings at $5.91 EPS.

Other equities analysts have also issued reports about the company. ValuEngine raised Bausch Health Companies from a “strong sell” rating to a “sell” rating in a research report on Monday, July 29th. Cantor Fitzgerald set a $32.00 target price on Bausch Health Companies and gave the company a “buy” rating in a research report on Friday, May 31st. HC Wainwright upped their target price on Bausch Health Companies from $50.00 to $54.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. Barclays set a $28.00 target price on Bausch Health Companies and gave the company a “buy” rating in a research report on Monday, July 8th. Finally, Zacks Investment Research raised Bausch Health Companies from a “hold” rating to a “buy” rating and set a $27.00 price target on the stock in a research report on Tuesday, May 21st. Three research analysts have rated the stock with a sell rating, three have given a hold rating and twelve have given a buy rating to the company’s stock. Bausch Health Companies presently has an average rating of “Buy” and an average price target of $29.68.

NYSE BHC opened at $20.88 on Thursday. The business has a 50 day moving average price of $23.79 and a two-hundred day moving average price of $23.91. Bausch Health Companies has a fifty-two week low of $17.20 and a fifty-two week high of $28.45. The stock has a market cap of $7.98 billion, a PE ratio of 5.19, a P/E/G ratio of 0.27 and a beta of 0.76. The company has a quick ratio of 0.92, a current ratio of 1.21 and a debt-to-equity ratio of 8.94.

Bausch Health Companies (NYSE:BHC) last released its quarterly earnings results on Tuesday, August 6th. The company reported $1.03 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.06 by ($0.03). The company had revenue of $2.15 billion during the quarter, compared to analysts’ expectations of $2.15 billion. Bausch Health Companies had a positive return on equity of 52.12% and a negative net margin of 10.88%. The firm’s revenue was up 1.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.93 EPS.

Several large investors have recently added to or reduced their stakes in the company. First Allied Advisory Services Inc. grew its stake in shares of Bausch Health Companies by 2.8% in the first quarter. First Allied Advisory Services Inc. now owns 18,341 shares of the company’s stock worth $453,000 after purchasing an additional 498 shares in the last quarter. Investors Research Corp grew its stake in shares of Bausch Health Companies by 85.7% in the second quarter. Investors Research Corp now owns 1,300 shares of the company’s stock worth $33,000 after purchasing an additional 600 shares in the last quarter. Cullinan Associates Inc. grew its stake in shares of Bausch Health Companies by 1.5% in the second quarter. Cullinan Associates Inc. now owns 47,033 shares of the company’s stock worth $1,186,000 after purchasing an additional 700 shares in the last quarter. Pictet Asset Management Ltd. grew its stake in shares of Bausch Health Companies by 0.6% in the second quarter. Pictet Asset Management Ltd. now owns 115,664 shares of the company’s stock worth $2,924,000 after purchasing an additional 700 shares in the last quarter. Finally, Cetera Investment Advisers grew its stake in shares of Bausch Health Companies by 7.0% in the first quarter. Cetera Investment Advisers now owns 11,102 shares of the company’s stock worth $273,000 after purchasing an additional 725 shares in the last quarter. 53.70% of the stock is owned by institutional investors.

In other news, EVP Christina Ackermann sold 3,418 shares of the stock in a transaction on Monday, August 12th. The stock was sold at an average price of $22.45, for a total value of $76,734.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 11.87% of the company’s stock.

Bausch Health Companies Company Profile

Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.

Recommended Story: What is a Market Correction?

Get a free copy of the Zacks research report on Bausch Health Companies (BHC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Bausch Health Companies (NYSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.